Navigation Links
Clinical Data Reinforce Safety and Efficacy of Boston Scientific's Two Drug- Eluting Stent Platforms
Date:3/29/2009

isks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward- looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.



    CONTACT:  Paul Donovan
              +1-508-650-8541 (office)
              +1-508-667-5165 (mobile)
              Med
'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
2. MitraClip(R) Therapy Data Shows Important Clinical Benefit in High Risk Patients With Functional Mitral Regurgitation at 12-Month Follow Up
3. Medgenics Phase I/II Clinical Trial Now Shows EPODURE Continuous Anemia Treatment Lasting 5 Months in Kidney Disease Patients
4. RenalGuard(R) Pilot Safety Clinical Trial Data to be Presented at ACC 2009
5. Phase IV Multi-center Clinical Study of Kutai Concludes in Nanjing
6. Joint Statement from the American Diabetes Association and American Association of Clinical Endocrinologists on the NICE-SUGAR Study on Intensive Versus Conventional Glucose Control in Critically Ill Patients
7. Abbott Advances Its Revolutionary Fully Bioabsorbable Drug Eluting Stent With Initiation of Next Phase of Clinical Trial
8. Radius Initiates Phase 2a Clinical Trial of RAD1901 in Menopausal Hot Flashes
9. Results From Efficacy and Safety Study of Cortheras Relaxin in Acute Heart Failure to be Presented at Late-Breaking Clinical Trials Session at ACC 58th Annual Scientific Session
10. U.S. Naval Medical Research Center Resubmits IND Application for Proposed RESUS Clinical Trial in Trauma Patients in the Out-of-Hospital Setting
11. Another LNA-based RNA Inhibitor Enters Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)...  BiOptix is pleased to announce the appointment of Dr. ... and Biochemistry. Scott joins the company after previous scientific leadership ... the course of his nearly 20 year career in ... nationally recognized thought leader in the biosensor field and ...
(Date:1/22/2015)... RMD ) today announced results for its quarter ... million, a 10 percent increase compared to the quarter ended ... currency basis). Net income was $91.2 million, an increase of ... Diluted earnings per share for the quarter were $0.64, an ...
(Date:1/22/2015)... Calif. , Jan. 22, 2015  Amgen (NASDAQ: AMGN ... full year 2014 financial results on Tuesday, Jan. 27, 2015, after ... followed by a conference call with the investment community at 2 ... Robert A. Bradway , chairman and chief executive officer, and other ...
Breaking Medicine Technology:BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2
... Sanofi Pasteur, the vaccines division of the sanofi-aventis ... has been awarded a three-year contract for $56.94 million ... (HHS) to maintain flocks to enable manufacturing pandemic influenza ... The contract supported by the HHS Biomedical Advanced ...
... Abbott Laboratories has agreed to voluntarily withdraw ... market because of clinical trial data indicating an ... U.S. Food and Drug Administration announced today. ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO ) "Meridia,s continued ...
Cached Medicine Technology:Sanofi Pasteur and U.S. Department of Health and Human Services Enter Into Agreement for Pandemic Vaccine Preparedness 2Sanofi Pasteur and U.S. Department of Health and Human Services Enter Into Agreement for Pandemic Vaccine Preparedness 3Sanofi Pasteur and U.S. Department of Health and Human Services Enter Into Agreement for Pandemic Vaccine Preparedness 4Abbott Laboratories Agrees to Withdraw Its Obesity Drug Meridia 2
(Date:1/22/2015)... January 22, 2015 The City of West Hollywood ... a.m., to commemorate the 42nd anniversary of the Supreme Court decision ... “It’s been 42 years since the Roe vs. Wade decision and ... as present as ever,” said City of West Hollywood Councilmember Abbe ...
(Date:1/22/2015)... 23, 2015 VogueQueen is a seasoned and ... and many designers are thrilled to have it lead the ... its new collection of prom dresses for the global market. ... the strategic vision and he focuses on continuing the goal ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has ... View website of AngelWeddingDress.com to find more ... dresses online for a bridal party. AngelWeddingDress offers a ... them. Its maternity wedding dresses are specially designed for ...
(Date:1/22/2015)... York, New York (PRWEB) January 22, 2015 ... filed after Fresenius Medical Care recalled its GranuFlo and ... federal multidistrict litigation underway in U.S. District Court, District ... Order dated January 20th, the Court has remanded a ...
(Date:1/22/2015)... 22, 2015 Joan Lunden, award-winning American ... at the upcoming 32nd Annual Miami Breast Cancer ... Education Resource®, LLC (PER®) , shares that “a fast-growing, ... undetected if she had not followed up her clean ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6
... Danaher Corporation (NYSE: DHR ... has approved a regular quarterly dividend of $0.03 ... holders of record on June 26, 2009.Danaher Corporation ... Technologies, Industrial Technologies and Tools and Components ( ...
... Fiscal third quarter revenue from continuing operations increased $25 million, or 5%, to $506 million ... , , , Fiscal ... , , , ... , , , ...
... 7 Abaxis, Inc. (Nasdaq: ABAX ), a ... that Don Wood, chief operations officer, will present at the ... on Thursday, May 14, 2009 at 10:00 a.m. ET. The ... York City.Interested investors are invited to listen to a live ...
... STE ) today announced that its Board of ... to $0.11 per common share. The dividend is payable ... of business on May 21, 2009. About STERIS ... healthier today and safer tomorrow through knowledgeable people and innovative ...
... National Organization Dedicated to Advancing the Patient ... The Quantum Group, a healthcare services organization ... the Patient-Centered Primary Care Collaborative (PCPCC). The ... consumer groups, patient quality organizations, health plans, ...
... Worldwide Forensic Casework Revenues Grow Significantly , , ... (Nasdaq: ORCH ), a leading worldwide provider of ... the first quarter of 2009.Total revenues were $14.0 million for ... the first quarter of 2008, despite the adverse impact of ...
Cached Medicine News:Health News:Perrigo Reports Record Third Quarter 2Health News:Perrigo Reports Record Third Quarter 3Health News:Perrigo Reports Record Third Quarter 4Health News:Perrigo Reports Record Third Quarter 5Health News:Perrigo Reports Record Third Quarter 6Health News:Perrigo Reports Record Third Quarter 7Health News:Perrigo Reports Record Third Quarter 8Health News:Perrigo Reports Record Third Quarter 9Health News:Perrigo Reports Record Third Quarter 10Health News:Perrigo Reports Record Third Quarter 11Health News:Perrigo Reports Record Third Quarter 12Health News:Perrigo Reports Record Third Quarter 13Health News:Perrigo Reports Record Third Quarter 14Health News:Perrigo Reports Record Third Quarter 15Health News:Perrigo Reports Record Third Quarter 16Health News:Perrigo Reports Record Third Quarter 17Health News:Perrigo Reports Record Third Quarter 18Health News:Perrigo Reports Record Third Quarter 19Health News:Perrigo Reports Record Third Quarter 20Health News:Perrigo Reports Record Third Quarter 21Health News:Perrigo Reports Record Third Quarter 22Health News:Abaxis, Inc. to Present at Bank of America and Merrill Lynch 2009 Health Care Conference 2Health News:STERIS Corporation Announces Quarterly Dividend Increase of 38% 2Health News:STERIS Corporation Announces Quarterly Dividend Increase of 38% 3Health News:The Quantum Group Joins Executive Committee of the Patient-Centered Primary Care Collaborative 2Health News:The Quantum Group Joins Executive Committee of the Patient-Centered Primary Care Collaborative 3Health News:The Quantum Group Joins Executive Committee of the Patient-Centered Primary Care Collaborative 4Health News:The Quantum Group Joins Executive Committee of the Patient-Centered Primary Care Collaborative 5Health News:The Quantum Group Joins Executive Committee of the Patient-Centered Primary Care Collaborative 6Health News:Orchid Cellmark Reports Improved First Quarter 2009 Financial Results 2Health News:Orchid Cellmark Reports Improved First Quarter 2009 Financial Results 3Health News:Orchid Cellmark Reports Improved First Quarter 2009 Financial Results 4Health News:Orchid Cellmark Reports Improved First Quarter 2009 Financial Results 5Health News:Orchid Cellmark Reports Improved First Quarter 2009 Financial Results 6Health News:Orchid Cellmark Reports Improved First Quarter 2009 Financial Results 7
Sensitive Eyes drops keep soft contact lenses moist....
... preservative free lubricating and rewetting ... eyes while you're wearing soft ... free formula is ideal for ... to preservatives and for frequent ...
For use to rewet and lubricate lenses during wear. Soothes and moisturizes eyes while wearing soft contact lenses....
... is the most convenient multi-purpose no rub ... bottle without the need to rub: cleans, ... removes protein build-up when used daily. Its ... a special ingredient that removes protein deposits ...
Medicine Products: